Clinical-Stage Program in Graft versus Host Disease ("GvHD")

Kalytera is developing a clinical-stage cannabidiol (“CBD”) medicine to prevent and treat Graft versus Host Disease (“GvHD”). GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death.

  • Prevention of GvHD
  • Treatment of Acute GvHD

Preclinical Product Candidates

Kalytera seeks to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. By modifying cannabinoid molecules, and molecules which regulate the endogenous cannabinoid signaling system, Kalytera seeks to improve pharmacokinetics and increase potency, potentially allowing for the development of drug candidates with improved activity.

  • Acne
  • Sepsis-induced Acute Renal Failure (“ARF”)
  • Severe Traumatic Brain Injury (“TBI”)
  • Adult Respiratory Distress Syndrome (“ARDS”)
  • Ulcerative Colitis (“UC”)
  • Bone Fracture Healing
  • Osteoporosis